

CONTENTS

Vol.44 No.2 March 2013

Japanese Journal of Clinical Pharmacology
and Therapeutics

Original Article

- Safety and Efficacy of AJG522 as a Bowel Cleansing Agent for
Colonoscopy in Healthy Japanese Subjects Hidetoshi FURUIE, et al. 53
- Risk Management for Reomodulin: With Special Reference to
All-Case Surveillance Katsuhito NIHASHI, et al. 61

Forum

- Performance and Problems of Electronic Remote Source Data Verification:
A Pilot Study of Inspection Data Presentation and Questionnaire Survey after Study Morihiro NOMURA, et al. 71

Review Article

- Drug-Drug Interactions of the Oral Spherical Activated Charcoal Kremez[®] Tsutomu KOTEGAWA, et al. 77

Proceedings of the 33rd Annual Meeting of the Japanese Society of Clinical Pharmacology and Therapeutics

- Contents 85
- “Achievements and Prospects of Pharmacogenomics (PGx) in Clinical Pharmacology” 87
- “Predictive Markers for Clinical Response and Adverse Effects of Selective Serotonin Reuptake Inhibitors” 109
- “Ethics in Clinical Trial in Japan: Is It Possible to Solve Double Standards?” 127
- “Towards the Establishment of Formal Regulatory System of Compassionate Use of Drugs in Japan” 149
- “Biobanks of Genes and Tissues and Digitization of All Medical Records” 171

Report

- Report of Trainee of the Foreign Clinical Pharmacology Training Program: No.1 Wakako NAKANO 181

Book Review

- Toshihiro HAMA 108

Drug Information

39E

Information for Authors

43E

Announcements

45E

Contents of Proceedings of the 33rd Annual Meeting of the Japanese Society of Clinical Pharmacology and Therapeutics

“Achievements and Prospects of Pharmacogenomics (PGx) in Clinical Pharmacology”

Preface		Hirotochi ECHIZEN, et al.	87
1.	Exploratory Studies of Genetic Markers for Drug Adverse Reactions by GWAS Approaches	Kouichi KUROSE, et al.	89
2.	Application of PGx for Prevention of Gastric Cancer by Eradication of <i>H. pylori</i>	Takahisa FURUTA, et al.	95
3.	The Situation and Future Prospects of Pharmacogenomics Consortium in Novel Drug Development	Akira SHINAGAWA	101
4.	Challenges on DNA Sample Collection for Future Use to Promote PGx-Based Medicine	Yoshiaki UYAMA	106

“Predictive Markers for Clinical Response and Adverse Effects of Selective Serotonin Reuptake Inhibitors”

Preface		Kazutaka SHIMODA, et al.	109
1.	Biological Markers for Predicting Efficacy and Tolerability in New Antidepressants	Reiji YOSHIMURA	110
2.	Influence of Pharmacokinetics of SSRI on Clinical Efficacy and Side Effects	Takashi WATANABE, et al.	114
3.	Prediction of Treatment Response in Depression Based on Genetic Factors from the Practical Viewpoint	Masaki KATO	117
4.	Determinant Factors of Therapeutic Response to SSRI	Norio YASUI- FURUKORI	123

“Ethics in Clinical Trial in Japan: Is It Possible to Solve Double Standards?”

1.	Background and Activities of Sub-Committee of Research Ethics, Committee of Academic Affairs, the Japanese Society of Clinical Pharmacology and Therapeutics (JSCPT)	Kiichiro TSUTANI	127
2.	Regulations of Clinical Research in Japan: An Historical Overview	Shimon TASHIRO	131
3.	The Double Standard of Institutional Review in University Hospital, Whether the Clinical Trials Aim at Approval or Not	Ryuji KOIKE	136
4.	The Past and Future of Ethical Guidelines for Clinical Studies	Noriko MORISHITA	141
5.	Ethical Review of Human Studies in Japan	Toshiyuki SASAGURI	145

“Towards the Establishment of Formal Regulatory System of Compassionate Use of Drugs in Japan”

Preface		Kiichiro TSUTANI, et al.	149
1.	Compassionate Use: Concept, Present Status in the World, and Challenge for Japan	Akio TERAOKA, et al.	153
2.	Pharmaceutical Industry’s Views on Compassionate Use of Medicinal Products (Access to Unapproved Drugs)	Masaaki KUWAHARA	157
3.	The Expanded Access Program in Japan	Toshio MIYATA	161
4.	Legal Issues on Compassionate Use --Toward a Legal Theory Construction that Enables Suitable Responses to the Needs When Necessary--	Tetsu ISOBE	167

“Biobanks of Genes and Tissues and Digitization of All Medical Records”

Summary		Toshiyuki SASAGURI, et al.	171
1.	Utilization of the Clinical Information for Pharmacoepidemiology	Yayoi NISHIDA, et al.	173
2.	The Challenge of Tohoku Medical Megabank Organization for Drug Developing through the Genomic Cohort in Disaster Area of East Japan Earthquake	Hideyasu KIYOMOTO	175
3.	Banking System and the Research Use of Human Tissue at Academia	Sachiko TAKENOSHITA-NAKAYA, et al.	177
4.	Ethical and Legal Ramifications of Biobanks and Health Information Databases	Eiji MARUYAMA	179